pyrazines has been researched along with Carcinoma, Ductal, Pancreatic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Assuncao, TM; Dusetti, N; Iovanna, J; Lomberk, G; Mathison, A; Salmonson, A; Toro-Zapata, J; Urrutia, G; Urrutia, R | 1 |
| Benson, AB; Davis, RE; Javle, M; Kumar-Sinha, C; Lopez, CD; Maitra, A; Mettu, NB; Munugalavadla, V; Neelapu, S; Overman, M; Parra, ER; Patel, P; Tao, L; Vats, P; Xiao, L | 1 |
| Brekken, RA; Hosein, AN; Maitra, A | 1 |
| Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J | 1 |
| Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
1 review(s) available for pyrazines and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Extracellular Fluid; Extracellular Matrix; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Permeability; Pressure; Protein Kinase Inhibitors; Pyrazines; rho-Associated Kinases; Sulfonamides; Tumor Microenvironment | 2020 |
1 trial(s) available for pyrazines and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Progression-Free Survival; Proof of Concept Study; Pyrazines; Tumor Microenvironment | 2020 |
3 other study(ies) available for pyrazines and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzimidazoles; Carcinoma, Pancreatic Ductal; Checkpoint Kinase 1; DNA Replication; Drug Synergism; Enzyme Inhibitors; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrazines; Pyrazoles; Random Allocation; Xenograft Model Antitumor Assays | 2020 |
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones | 2018 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |